Cartesian Therapeutics Inc. logo

Cartesian Therapeutics Inc. (RNAC)

Market Closed
18 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
11. 84
-0.69
-5.51%
Pre Market
$
10. 66
-1.18 -9.97%
344.41M Market Cap
- P/E Ratio
0% Div Yield
61,400 Volume
- Eps
$ 12.53
Previous Close
Day Range
11.82 12.79
Year Range
8.46 26.5
Want to track RNAC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 22 days

Summary

RNAC closed Friday lower at $11.84, a decrease of 5.51% from Thursday's close, completing a monthly increase of 15.18% or $1.56. Over the past 12 months, RNAC stock lost -34.19%.
RNAC is not paying dividends to its shareholders.
The last earnings report, released on May 06, 2025, exceeded the consensus estimates by 0.23%. On average, the company has surpassed earnings expectations by 0.04%, based on the last three reports. The next scheduled earnings report is due on Aug 14, 2025.
Cartesian Therapeutics Inc. has completed 2 stock splits, with the recent split occurring on Apr 05, 2024.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

RNAC Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Cartesian Therapeutics: Uncertainty Remains

Cartesian Therapeutics: Uncertainty Remains

Cartesian Therapeutics' stock has rebounded sharply recently despite no significant news, driven partly by insider buying after a disappointing Phase 2b trial for Descartes-08 in myasthenia gravis. The company leverages its RNA Armory platform for mRNA cell therapies, focusing on autoimmune diseases, with Descartes-08 and Descartes-15 as its main assets. Descartes-08 showed mixed results in Phase 2b for MG, raising concerns due to endpoint changes and trial anomalies, yet plans continue for a pivotal trial in 2025.

Seekingalpha | 8 months ago
Cartesian Therapeutics, Inc. (RNAC) Reports Q3 Loss, Lags Revenue Estimates

Cartesian Therapeutics, Inc. (RNAC) Reports Q3 Loss, Lags Revenue Estimates

Cartesian Therapeutics, Inc. (RNAC) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $2.40 per share a year ago.

Zacks | 8 months ago
Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last?

Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last?

Cartesian Therapeutics, Inc. (RNAC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks | 9 months ago

Cartesian Therapeutics Inc. Dividends

RNAC is not paying dividends to its shareholders.

Cartesian Therapeutics Inc. Earnings

14 Aug 2025 (In 3 weeks) Date
-
Cons. EPS
-
EPS
6 May 2025 Date
-
Cons. EPS
-
EPS
5 Mar 2025 Date
-
Cons. EPS
-
EPS
11 Nov 2024 Date
-
Cons. EPS
-
EPS
15 Aug 2024 Date
-
Cons. EPS
0.54
EPS
RNAC is not paying dividends to its shareholders.
14 Aug 2025 (In 3 weeks) Date
-
Cons. EPS
-
EPS
6 May 2025 Date
-
Cons. EPS
-
EPS
5 Mar 2025 Date
-
Cons. EPS
-
EPS
11 Nov 2024 Date
-
Cons. EPS
-
EPS
15 Aug 2024 Date
-
Cons. EPS
0.54
EPS

Cartesian Therapeutics Inc. (RNAC) FAQ

What is the stock price today?

The current price is $11.84.

On which exchange is it traded?

Cartesian Therapeutics Inc. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is RNAC.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 344.41M.

When is the next earnings date?

The next earnings report will release on Aug 14, 2025.

Has Cartesian Therapeutics Inc. ever had a stock split?

Cartesian Therapeutics Inc. had 2 splits and the recent split was on Apr 05, 2024.

Cartesian Therapeutics Inc. Profile

Biotechnology Industry
Healthcare Sector
Carsten Brunn CEO
NASDAQ (NMS) Exchange
816212302 Cusip
US Country
66 Employees
- Last Dividend
5 Apr 2024 Last Split
- IPO Date

Overview

Cartesian Therapeutics, Inc. is a trailblazing clinical-stage biotechnology firm dedicated to advancing the field of medicine through its innovative approach in mRNA cell therapies. With a focus on treating various autoimmune diseases, the company stands at the forefront of developing therapies that aim to revolutionize the way such conditions are treated. Cartesian Therapeutics is founded on a commitment to leveraging advanced science to create impactful solutions for patients struggling with autoimmune disorders. Headquartered in Gaithersburg, Maryland, the company embodies a spirit of innovation and a relentless pursuit of excellence in biotechnology.

Products and Services

Cartesian Therapeutics, Inc. has developed a robust pipeline of groundbreaking mRNA cell therapies designed to address a wide range of autoimmune diseases through innovative treatment modalities. Here's an overview of their leading products under development:

  • Descartes-08: This cutting-edge product is an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell (CAR-T) therapy, which is currently in Phase 2b clinical development. It's specifically designed for treating generalized myasthenia gravis and is also being evaluated for its potential in treating patients with systemic lupus erythematosus. Furthermore, Descartes-08 is involved in myeloma autoimmune basket trials, exploring its utility in other autoimmune diseases.
  • Descartes-15: Aimed at addressing both autoimmune diseases and myeloma, Descartes-15 represents another significant stride in Cartesian Therapeutics' pursuit of novel treatments. While specific details regarding its mechanism of action and development stage remain concise, Descartes-15 underscores the company's commitment to broadening its impact across multiple autoimmune conditions.
  • Descartes-33: This product is currently in preclinical development and showcases Cartesian Therapeutics' ongoing efforts to extend its research and development into new therapeutic areas. Descartes-33 is focused on treating autoimmune diseases, indicating the company's continuous endeavor to innovate and expand its portfolio of solutions for autoimmune disorders.

Contact Information

Address: 65 Grove Street
Phone: 617 923 1400